GLP-1 receptor agonists linked to reduced risk of eye inflammation, Cleveland Clinic study shows
Key Takeaways:
- Researchers at the Cleveland Clinic Cole Eye Institute found that GLP-1 receptor agonist (GLP-1RA) therapy was associated with a significantly lower risk of developing non-infectious uveitis, an inflammatory eye condition that can cause permanent vision loss.
- Analysis of data from over 516,000 patients showed that people prescribed GLP-1RAs had about a 50 percent lower risk of new onset uveitis compared to those who had never taken these drugs.
- The findings suggest GLP-1RAs may have anti-inflammatory benefits beyond blood sugar and weight management, opening up the possibility of new protective applications in autoimmune and inflammatory eye diseases.
Understanding uveitis and its impact
Uveitis is an inflammatory condition that affects the uvea, the middle layer of the eye, and can extend to nearby structures such as the retina. Symptoms often include eye pain, redness, and blurred vision. In severe or untreated cases, uveitis can lead to irreversible vision loss. Globally, there are approximately 4 million new diagnoses every year.
The condition is primarily driven by inflammation inside the eye and is often associated with autoimmune or systemic inflammatory diseases, such as sarcoidosis, ankylosing spondylitis, and inflammatory bowel disease. Current treatments typically involve steroids, while people with chronic forms may require long-term immunosuppressive therapy.
Research overview
The Cleveland Clinic retrospective cohort study was published in JAMA Ophthalmology and conducted by researchers at the Cole Eye Institute. Using the TriNetX platform – a large-scale database containing de-identified electronic health records from more than 120 million patients across over 60 healthcare organisations – the team examined data spanning 2006 to 2025.
The study assessed records from 516,052 patients. This included:
- 258,026 patients prescribed GLP-1RA therapy (irrespective of whether they had diabetes).
- 258,026 matched controls who had never been prescribed a GLP-1RA but who may have used other diabetes treatments such as insulin or metformin.
The data was further analysed across four distinct cohorts:
- An overall cohort.
- Patients with diabetes.
- Patients with type 2 diabetes.
- Patients without diabetes.
Equal numbers of patients were included in the control groups for each cohort.
Findings and protective association
Primary analysis measured the risk of uveitis after the first GLP-1RA prescription, with further assessments carried out at one, three, and five years following treatment initiation.
In the overall cohort, GLP-1RA use was associated with a 51.7 percent relative risk reduction for newly diagnosed non-infectious uveitis. The protective effect was consistent across all subgroups, with people prescribed GLP-1RAs showing around a 50 percent lower risk compared to those who had never used these drugs.
Importantly, these results were observed when compared not only with the general control group but also with patients taking insulin or metformin, two commonly prescribed diabetes medications.
Implications for people at higher risk
Certain populations face a heightened risk of uveitis, including individuals with a family history, genetic predispositions, or those living with autoimmune diseases. For these groups, the findings carry particular significance.
“For patients in these populations who meet the indication for diabetic or weight loss medication, this research is promising because being prescribed GLP-1RAs may have the additional benefit of decreasing the risk of new onset non-infectious uveitis,” the authors noted.
Expert commentary
Dr Sumit Sharma, a retina and uveitis specialist at the Cleveland Clinic Cole Eye Institute and senior author of the study, emphasised the broader significance of the findings:
“This is the first study to find a protective effect of GLP-1RA therapy for autoimmune disease, which is very exciting and shows a further benefit of these drugs for patients beyond just weight loss and control of diabetes.”
Looking ahead
While further research is required to confirm and expand upon these findings, the study provides strong evidence that GLP-1RAs may offer benefits beyond glycaemic control and weight management. In addition to their established roles in type 2 diabetes and obesity care, these medications could potentially reduce the risk of inflammatory eye diseases such as uveitis.
This emerging evidence contributes to a growing understanding of the broader systemic effects of GLP-1RA therapy, highlighting its potential to reshape care for both metabolic and inflammatory conditions.
